NCT01894308View on ClinicalTrials.gov

A Dose Ranging Study to Examine TDS-Testosterone 5%

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions
Hypogonadotropism
Interventions
DRUG

Testosterone

10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

DEVICE

Pump Sprayer

A dose of product solution is delivered by means of a metered pump spray.

Trial Locations (1)

NW1 4LJ

Advanced Therapies Centre, The London Clinic, London

All Listed Sponsors
collaborator

Advanced Therapies Centre, The London Clinic

OTHER

lead

Transdermal Delivery Solutions Corp

INDUSTRY